#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

An atypical finding on scintigraphy with 99mTc-DPD, AL amyloidosis. Case report.


Authors: O. Kraft 1,2;  G. Havlová 1;  M. Havel 1,2;  V. Židlík 3,2;  E. Kapsová 4
Published in: NuklMed 2025;14:7-10
Category: Casuistry

Overview

In our practice, we encountered an atypical scintigraphic finding in a patient who was examined for suspected cardiac amyloidosis.

We were somewhat surprised by the scintigraphic findings after the application of 99mTc-DPD, in which there was a complete lack of radioindicator deposition in the skeleton, significant accumulation was in the lungs, and to a lesser extent in the myocardium. We, therefore, repeated the examination in another week. The finding was identical to that  performed a week ago. At the same time, a hematological diagnosis was carried out and everything was finally clarified by the fact that the patient was diagnosed with AL amyloidosis. In the case of suspicion of cardiac amyloidosis, a hematological examination is always performed and all findings must be evaluated.

Keywords:

AL amyloidosis – scintigraphy – TTR amyloidosis – 99mTc-DPD


Sources
  1. Mesquita CT, Brandão SCS, Glavam AP (2023). The Role of Nuclear Medicine in the Diagnosis of Amyloidosis. In: Xavier de Ávila, D., Villacorta Junior, H. (eds) Amyloidosis and Fabry Disease. Springer, Cham. https://doi.org/10.1007/978-3-031-17759-0_19.
  2. National Institutes of Health: U.S. National Library of Medicine. HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis). https://clinicaltrials.gov/ct2/show/NCT03759379. Accessed October 21, 2021.
  3. Habtemariam BA, Karsten V, Attarwala H et al. Clin Pharmacol Ther. 2021;109:372-382
  4. National Institutes of Health: U.S. National Library of Medicine. HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy. https://clinicaltrials.gov/ct2/show/NCT04153149. Accessed October 21, 2021.
  5. Ruberg F, Grogan M, Hanna M et al. Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review J Am Coll Cardiol. 2019;73:2872-2891  doi: 10.1016/j.jacc.2019.04.003.
  6. Kittleson MM, Maurer MS, Ambardekar AV et al. Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association. Circulation. 2020;142:e7-e22
  7. Garcia-Pavia P, Rapezzi C, Adler Y et al. Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on myocardial and pericardial diseases. Eur J Heart Fail 2021;23:512–526
  8. Li W, Uppal D, Wang YC et al. Nuclear imaging for the diagnosis of cardiac amyloidosis in 2021. Diagnostics. 2021;11(6):1–13
  9. Wang TKM, Hassan OKA, Jaber W, et al. Multi-modality imaging of cardiac amyloidosis: Contemporary update. World J. Radiol 2020;12:87–100
  10. Gillmore JD, Maurer MS, Falk RH et al. Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation 2016;133:2404–2412
  11. Pika T, Lochman P, Minařík J et al. Význam stanovení sérových hladin volných lehkých řetězců imunoglobulinu u AL amyloidózy. Transfuze Hematol. Dnes 2013;19:134–138
  12. Shukla AK, Kumar U. Positron emission tomography: An overview. J Med Phys 2006;31:13–21
  13. Dorbala S, Vangala D, Semer J et al. Imaging cardiac amyloidosis: A pilot study using 18F-florbetapir positron emission tomography. Eur J Nucl Med Mol. Imaging 2014;41:1652–1662
  14. Cassano RC, Genovesi D, Vergaro G et al. [18F]-florbetaben PET/CT is sensitive for cardiac AL amyloidosis. Eur J Clin Invest 2024;00:e14270.17 https://doi.org/10.1111/eci.14270.
  15. Lee SP, Lee ES, Choi H et al. 11C-Pittsburgh B PET Imaging in Cardiac Amyloidosis. JACC Cardiovasc Imaging 2015;8:50–59
  16. Lee JH, Lee GY, Kim SJ et al. Imaging Findings and Literature Review of 18F-FDG PET/CT in Primary Systemic AL Amyloidosis. Nucl Med Mol Imaging 2015;49:182–190
  17. Zhang LX, Martineau P, Finnerty V et al. Comparison of 18F-sodium fluoride positron emission tomography imaging and 99mTc-pyrophosphate in cardiac amyloidosis. J Nucl Cardiol 2022;29:1132-1140
  18. Kim YJ, Ha S. Cardiac amyloidosis imaging with amyloid positron emission tomography: A systematic review and metaanalysis. J Nucl Cardiol 2020;27:123–132
  19. Zoller M, Hajnos G, Burkhard R, et al.  99mTc-DPD-scintigraphy with intense uptake in fat tissue caused by AL-amyloidosis .Eur J Nucl Med Mol. Imaging 2016;43:2269–2270 https://doi.org/10.1007/s00259-016-3446-x.
  20. Quarta CC, Zheng J, Hutt D et al. 99mTc-DPD scintigraphy in immunoglobulin light chain (AL) cardiac amyloidosis. Eur Heart J Cardiovasc Imaging 2021;22:1304–1311
  21. Malka N, Abulizi M, Kharoubi M et al. Extracardiac soft tissue uptake, evidenced on early 99mTc-HMDP SPECT/CT, helps typing cardiac amyloidosis and demonstrates high prognostic value. Eur J Nucl Med Mol Imaging 2020;47:2396-2406
  22. Cappelli F, Gallini C, Costanzo EN et al. Lung uptake during 99mTc-hydroxymethylene diphosphonate scintigraphy in patient with TTR cardiac amyloidosis: An underestimated phenomenon. Int J Cardiol 2018;254:346-350
  23. Mattana F, Muraglia L, Girardi F et al. Clinical application of cardiac scintigraphy with bone tracers: controversies and pitfalls in cardiac Amyloidosis. Vessel Plus 2022;6:13-24
  24. McDonagh TA, Metra M, Adamo M et al. ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. Originální verze volně dostupná na webu https://academic.oup.com/eurheartj/article/42/36/3599/6358045 a vyšla v časopise Eur J Heart Fail 2022;24:4–131. doi: 10.1002/ejhf.2333.
Labels
Nuclear medicine Radiodiagnostics Radiotherapy
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#